Development and approval of the trifunctional antibody catumaxomab (anti-EpCAM×anti-CD3) as a targeted cancer immunotherapy
Authors:
- Diane SeimetzDSDiane Seimetz
- Horst LindhoferHLHorst Lindhofer
- Carsten BokemeyerCBCarsten Bokemeyer
- 1 October 2010
- journal article
- review article
- Published by Elsevier in Cancer Treatment Reviews
- Vol. 36 (6) , 458-467
Abstract
No abstract availableKeywords
This publication has 62 references indexed in Scilit:
- Induction of anti-tumor immunity by trifunctional antibodies in patients with peritoneal carcinomatosisJournal of Experimental & Clinical Cancer Research, 2009
- Distinct Populations of Cancer Stem Cells Determine Tumor Growth and Metastatic Activity in Human Pancreatic CancerCell Stem Cell, 2007
- Epithelial Cell Adhesion MoleculeThe American Journal of Pathology, 2007
- Characterisation of the new EpCAM-specific antibody HO-3: implications for trifunctional antibody immunotherapy of cancerBritish Journal of Cancer, 2007
- Pattern and prognostic factors in patients with malignant ascites: a retrospective studyAnnals of Oncology, 2007
- EpCAM (CD326) finding its role in cancerBritish Journal of Cancer, 2007
- Malignant ascites: Systematic review and guideline for treatmentEuropean Journal of Cancer, 2006
- Serial killing of tumor cells by cytotoxic T cells redirected with a CD19‐/CD3‐bispecific single‐chain antibody constructInternational Journal of Cancer, 2005
- Normal Human Immune Peritoneal Cells: Subpopulations and Functional CharacteristicsScandinavian Journal of Immunology, 1996
- Malignant ascites: a 2-year review from a teaching hospitalEuropean Journal of Surgical Oncology, 1996